SCHEMBL5052147

SCHEMBL5052147

CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(-c4cn[nH]c4)c3)cc2F)n(-c2ccc3[nH]ncc3c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.48
SYK P43405 8/20 0.48
SRC P12931 7/20 0.48
GSK3A P49840 5/20 0.47
BRAF P15056 5/20 0.45
ABL1 P00519 2/20 0.45
FLT1 P17948 2/20 0.45
KDR P35968 2/20 0.45
PLK4 O00444 1/20 0.45
ACOX3 O15254 1/20 0.45
MAP3K7 O43318 1/20 0.45
DYRK3 O43781 1/20 0.45
JAK2 O60674 1/20 0.45
ERN1 O75460 1/20 0.45
RPS6KA4 O75676 1/20 0.45
STK10 O94804 1/20 0.45
MAP4K4 O95819 1/20 0.45
RAF1 P04049 1/20 0.45
NTRK1 P04629 1/20 0.45
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5055072 0.91 MAPK14 (0.48) MAPK14SYKSRCGSK3ABRAF
SCHEMBL5052144 0.90 MAPK14 (0.58) MAPK14SYKSRCBRAFABL1
SCHEMBL5056525 0.90 MAPK14 (0.48) MAPK14SYKSRCBRAFABL1
SCHEMBL2030273 0.89 BRAF (0.59) MAPK14SYKSRCBRAFABL1
SCHEMBL5055273 0.88 MAPK14 (0.46) MAPK14SYKSRCBRAFABL1
SCHEMBL5052148 0.88 MAPK14 (0.44) MAPK14SYKSRCBRAFABL1
SCHEMBL2029196 0.88 MAPK14 (0.52) MAPK14SYKSRCGSK3ABRAF
SCHEMBL5055024 0.88 MAPK14 (0.58) MAPK14SYKSRCGSK3ABRAF
SCHEMBL5059900 0.87 MAPK14 (0.52) MAPK14SYKSRCGSK3ABRAF
SCHEMBL5052226 0.86 MAPK14 (0.47) MAPK14SYKSRCBRAFABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPK14 29/4885SYK 392/4885SRC 232/4885
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 MAPK14 100/4885SYK 92/4885SRC 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.